companies

Anaconda Biomed

Founded 2015
Employees 20+
Primary contact
Carrer d'Eivissa, 56
Sant Quirze del Vallès
08192 Barcelona
Catalonia
Spain
+34 933 900 508
Links
https://anaconda.bio/
Diseases & Conditions
Sections
Anaconda Biomed is developing the next generation of catheters to perform safely and efficiently mechanical thrombectomies. Its flagship product is the ANA (Advanced Neurovascular Access) Catheter System, which consists of unique, funnel-shaped delivery and aspiration catheters to be used in combination with a stent retriever. When deployed, the funnel self-expands and directly conforms to the artery diameter up to 5mm. It is designed to locally restrict flow and allow full thrombus extraction without fragmentation.
Select partners: Creganna Medical, Vall d'Hebron.
Founded 2015
Employees 20+
Primary contact
Carrer d'Eivissa, 56
Sant Quirze del Vallès
08192 Barcelona
Catalonia
Spain
+34 933 900 508
Links
https://anaconda.bio/
Diseases & Conditions
Sections

Funding 💰

Total $39M
Select investors Ysios Capital, Innogest Capital, Omega Funds, Asabys Partners, CDTI, Banco Sabadell

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Important market: Stroke is the fifth leading cause of death in the U.S. and a leading cause of disability, according to the American Heart Association/American Stroke Association (AHA/ASA). Additionally, every 2 seconds - someone in the world is undergoing a stroke. Every 10 seconds, someone in the world dies from a stroke. In the USA alone, there are about 690,000 annual incidences of AIS (Acute Ischemic Stroke).
  • Clinical studies are underway: Anaconda Biomed's ANA system is currently under regulatory clearance, and the first results show a high rate of complete recanalization and favorable 90-day outcomes. 🔗
  • Great team: The company has been preparing for growth and has been hiring executives during the past couple of years. Also, it has assembled a strong scientific board to help it bring its ANA system to hospitals around Europe and later, North America. 🔗

Video ▶️

Awards & Recognitions 🏆

  • 2020 Ignasi Pujol Award by Diari ARA 🔗
  • 2020 El Periódico de Catalunya: Best company of the year 🔗
  • 2019 REVOLUCIÓ 4.0: Health Technological Award 🔗

Quotes 💬

“
The investment in Anaconda Biomed is great news not only for the consolidation of the medtech ecosystem in Spain and Barcelona but also for the amazing work of the founders in putting together a disruptive medical device by combining excellent medicine with high tech chemistry.
— Josep L. Sanfeliu, partner at Ysios Capital 🔗
“
We are very pleased for this sizable investment round following our first seed investment in Anaconda Biomed's one year ago. With its innovative design addressing a clear clinical need and a capable management team, Anaconda Biomed is well positioned to be a winner in the high growth stroke treatment market and a success story for European medtech industry.
— Claudio Rumazza, partner at Innogest Capital 🔗
“
Mechanical thrombectomy is quickly becoming a game changing procedure for ischemic stroke patients. Our analysis suggests that Anaconda's innovative device may become the next generation device and therefore a market leader.
— Claudio Nessi, partner at Omega Funds 🔗
Last update: January 13, 2023